BioXcel Therapeutics, Inc. (BTAI) Latest Company News

Sep 1, 2026, 11:27 UTC
BioXcel Therapeutics entered into a super-priority senior secured priming debtor-in-possession credit agreement providing up to $77.25 million in aggregate principal, including $19 million new money loans and $58.25 million roll-up loans, with an initial draw of $9.5 million.
Aug 31, 2026, 16:41 UTC
Teva Pharmaceutical Industries has made a bid to acquire certain assets of BioXcel Therapeutics, including the product Igalmi and a potential at-home agitation treatment, to expand its neuroscience portfolio.
Source:
- zacks.com
Aug 28, 2026, 10:00 UTC
BioXcel Therapeutics entered into an asset sale agreement with Teva Pharmaceuticals, which will act as the stalking horse bidder in a court-supervised 363 auction process.
Source:
Aug 28, 2026, 02:42 UTC
BioXcel Therapeutics, an AI-driven biopharmaceutical company, filed for Chapter 11 bankruptcy protection in the United States on Thursday.
Source:
- reuters.com
Aug 25, 2026, 00:00 UTC
BioXcel Therapeutics entered into the Fourteenth Amendment to its Credit Agreement, obtaining $1.25 million in additional term loans and reducing its minimum liquidity covenant from $3.0 million to $250,000.
Aug 24, 2026, 00:00 UTC
BioXcel Therapeutics entered into the Thirteenth Amendment to its Credit Agreement and Guaranty, extending the deadline to August 28, 2026 for the borrower to enter into definitive agreements for an acceptable transaction (full repayment or alternative capital solution), amending the prior Eleventh Amendment's milestone and cooperation requirements.
Aug 14, 2026, 00:11 UTC
BioXcel Therapeutics, Inc. reported a Q2 2026 net loss of $0.49 per share, beating the Zacks Consensus Estimate of a $0.51 loss and improving from a $2.45 loss per share a year ago.
Source:
- zacks.com
Aug 11, 2026, 00:00 UTC
BioXcel Therapeutics amended its credit agreement, extending the deadline to enter an acceptable capital transaction from August 10, 2026 to August 21, 2026, and reducing the minimum liquidity covenant from $6.25 million to $3.0 million.
Aug 3, 2026, 00:00 UTC
BioXcel Therapeutics entered into the Eleventh Amendment to its credit agreement with Oaktree lenders, deferring a $9.02 million principal and interest payment to August 31, 2026, reducing the minimum liquidity covenant to $6.25 million, and requiring an acceptable capital transaction by August 10, 2026.
Jul 6, 2026, 00:00 UTC
BioXcel Therapeutics entered into the Tenth Amendment to its Credit Agreement and Guaranty, capitalizing accrued unpaid interest, deferring a $9,016,914.47 payment from June 30, 2026 to July 31, 2026, and reducing the minimum liquidity covenant from $12.5 million to $7.5 million.

BTAI

BioXcel Therapeutics entered into a super-priority senior secured priming debtor-in-possession credit agreement providing up to $77.25 million in aggregate principal, including $19 million new money loans and $58.25 million roll-up loans, with an initial draw of $9.5 million.

Teva Pharmaceutical Industries has made a bid to acquire certain assets of BioXcel Therapeutics, including the product Igalmi and a potential at-home agitation treatment, to expand its neuroscience portfolio.

BioXcel Therapeutics entered into an asset sale agreement with Teva Pharmaceuticals, which will act as the stalking horse bidder in a court-supervised 363 auction process.

BioXcel Therapeutics, an AI-driven biopharmaceutical company, filed for Chapter 11 bankruptcy protection in the United States on Thursday.

BioXcel Therapeutics entered into the Fourteenth Amendment to its Credit Agreement, obtaining $1.25 million in additional term loans and reducing its minimum liquidity covenant from $3.0 million to $250,000.

BioXcel Therapeutics, Inc. reported a Q2 2026 net loss of $0.49 per share, beating the Zacks Consensus Estimate of a $0.51 loss and improving from a $2.45 loss per share a year ago.

BioXcel Therapeutics amended its credit agreement, extending the deadline to enter an acceptable capital transaction from August 10, 2026 to August 21, 2026, and reducing the minimum liquidity covenant from $6.25 million to $3.0 million.

BioXcel Therapeutics entered into the Tenth Amendment to its Credit Agreement and Guaranty, capitalizing accrued unpaid interest, deferring a $9,016,914.47 payment from June 30, 2026 to July 31, 2026, and reducing the minimum liquidity covenant from $12.5 million to $7.5 million.